Cough Suppressant Drugs Market- Insights
A cough is a very common symptom of various upper and lower respiratory tract infections. It is a reflex response to mechanical, chemical, or inflammatory irritation of the tracheobronchial tree, which is conveyed by sensory neurons in the airways reflexly through neurons present in the brainstem. Antitussives, also known as cough suppressants, are widely used to relieve the symptoms of cough. Cough suppressant works by reducing the activity of cough reflex and suppresses the urge to cough. Dextromethorphan and Codeine are the two most common cough suppressant drugs widely used in the treatment of cough.
Frequent approvals and launch of new cough suppressant drugs and high prevalence of cough is expected to drive the market growth
In March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive. Approval and launch of such new drugs in the market is expected to drive the cough suppressant drugs market growth over the forecast period.
High prevalence of cough is also expected to be a major factor for rising demand for cough suppressant drugs, which drives the market growth. For instance, according to the data published by the National Center for Biotechnology Information in 2014, cough is the most common reason for visits to primary care physicians globally, accounting for around 8% of all consultations. According to the same source, the annual prevalence of cough in the general population is reported as approximately 10–33% globally.
The global cough suppressant drugs market size was valued at US$ 1100.4 Mn in 2017 and is expected to witness a CAGR of 3.7% during the forecast period (2018 – 2026).
North America is expected to hold dominant position, owing to frequent approvals of new cough suppressant drugs by FDA
North America cough suppressant market is expected to show good growth over the forecast period, owing to frequent approvals to novel drugs by the FDA. For instance, in 2015, Vernalis plc and Tris Pharma Inc. received the U.S. Food and Drug Administration (FDA) approval for the New Drug Application (NDA) for Tuzistra XR (codeine polistirex and chlorpheniramine polistirex) extended-release oral suspension, CIII (DEA Schedule III). Tuzistra XR is a codeine-based extended-release oral suspension for cough-cold treatment.
Figure 1. Global Cough Suppressant Drugs Market Share (%) Analysis, By Region, 2026
Source: Coherent Market Insights Analysis (2017)
Key players in the market are involved in strategic mergers and partnerships, in order to develop, manufacture, and sell novel cough suppressant drugs and to gain major market share.
For instance, in 2015, Tris Pharma, Inc. entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare (a part of Pfizer Inc.). According to the agreement, Pfizer Consumer Healthcare will commercialize Tris’ extended release dextromethorphan cough syrup under the Robitussin Brand. In exchange, Tris will provide the U.S. branded rights to its protected intellectual property for an extended release dextromethorphan formulation to Pfizer Consumer Healthcare and Tris will receive an upfront payment, milestone payments, and sales-based royalties.
Figure 2. Global Cough Suppressant Drugs Market Share (%) Analysis, By Distribution Channel, 2026
Various new players are entering lucrative cough suppressant drugs market by partnering with other manufacturers. For instance, in November 2018, Aytu BioScience, Inc., a specialty pharmaceutical company, entered into the cough suppressant drugs market with an exclusive license of FDA-approved Tuzistra XR from Tris Pharma Inc. Along with Tuzistra XR, Aytu BioScience, Inc. also has a licensed complementary antitussive product with pending FDA approval.
However, stringent regulations against the use of cough suppressant is expected to affect the global cough suppressant drugs market growth over the forecast period.
For instance, in February 2018, the Therapeutic Goods Administration reclassified codeine as prescription only medicine in Australia, which was previously available as over-the-counter medication. This reclassification was made, as regular use of medicines containing codeine may lead to its addiction.
In January 2018, the U.S. Food and Drug Administration made safety labeling changes to limit the use of codeine or hydrocodone containing prescription opioid cough and cold medicines in children younger than 18 years old to protect kids from serious risks of opioid ingredients containing cough treatment drugs. After the safety labeling changes, these products will no longer be indicated for treatment of cough in pediatric population and will be labeled for use only in adults aged 18 years and older.
Key players operating in the global cough suppressant drugs market include Perrigo Company plc, Vernalis plc, Tris Pharma Inc., Pfizer Inc., Aytu BioScience, Inc., Acella Pharmaceuticals LLC, Mayne Pharma Inc., Taro Pharmaceutical Industries Ltd., Amneal Pharmaceuticals LLC, Aurobindo Pharma Ltd, and GlaxoSmithKline plc.
A cough is a most common symptom of various upper and lower respiratory tract infections. It affects a large proportion of the population leading them to seek medical attention. According to the data published by Journal of the Association of Physicians of India in 2016, cough was identified as the sixth most common reason for hospital outpatient department visits. Cough suppressants, also known as antitussives, are medications that help to suppress cough. Some of the examples of cough suppressants are Dextromethorphan, Codeine, Noscapine, Butamirate, Benzonatate, and Pholcodine. Dextromethorphan and Codeine are the most common and widely used cough suppressant in market.
Frequent launch of new cough suppressants in the market by key players is expected to drive the cough suppressant drugs market growth over the forecast period. For instance, in March 2018, Perrigo Company plc. received the FDA approval for the brand OTC equivalent of Mucinex DM Maximum Strength (Guaifenesin and Dextromethorphan Hydrobromide Extended-release Tablets, 1200 mg/60 mg). Mucinex DM Maximum Strength is indicated to control coughs and to break up mucus, making coughs more productive.
Various key players in the market are conducting research and are evaluating safety and efficacy of various drugs for the treatment of cough. Such initiatives taken by companies is expected to lead to the development of new cough suppressant drugs.
For instance, CSPC ZhongQi Pharmaceutical Technology Co., Ltd. is evaluating the efficacy and safety of benzonatate soft capsules for improving adult cough symptoms, wherein the study is currently (2018) under phase 3 clinical trial.
Moreover, high prevalence of cough is expected to increase the demand for cough suppressant drugs, thereby driving the market growth. For instance, according to the study published by the National Center for Biotechnology Information in 2013, cough is a very common condition and around 12% of the people in Britain experience chronic cough, daily or weekly.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.
Table of Contents
*Browse 42 market data tables and 40 figures on “Cough Suppressant Drugs Market - Global forecast to 2026”.
Coherent Market Insights followsa comprehensive research methodology focused on providing the most precise market analysis. The company leverages a data triangulation model which helps company to gauge the market dynamics and provide accurate estimates. Key components of the research methodologies followed for all our market reports include:
In addition to this, Coherent Market Insights has access to a wide range of the regional and global reputed paid data bases, which helps the company to figure out the regional and global market trends and dynamics. The company analyses the industry from the 360 Degree Perspective i.e. from the Supply Side and Demand Side which enables us to provide granular details of the entire ecosystem for each study. Finally, a Top-Down approach and Bottom-Up approach is followed to arrive at ultimate research findings.
Coherent Market Insights desk research is based on a principle set of research techniques:
Coherent Market Insights has a large amount of in-house repository of industry database. This is leveraged as a burner for initiating a new research study. Key secondary sources include:
Preliminary Data Mining
The raw data is obtained through the secondary findings, in house repositories, and trade surveys. It is then filtered to ensure that the relevant information including industry dynamics, trends, and outlook is retained for further research process.
Holistic approach is used to ensure that the granular and uncommon parameters are taken into consideration to ensure accurate results. The information from the paid databases are further combined to the raw data in order to standardize it.
Coherent Statistical model
We arrive at our final research findings through simulation models. Coherent Data Analytics Model is a statistical tool that helps company to forecast market estimates. Few of the parameters considered as a part of the statistical model include:
Once the findings are derived from the statistical model, large volume of data is process to confirm accurate research results. Data analytics and processing tools are adopted to process large chunk of collected informative data. In case, a client customizes the study during the process, the research finding till then are benchmarked, and the process for new research requirement is initiated again.
This is the most crucial stage of the research process. Primary Interviews are conducted to validate the data and analysis. This helps in achieving the following purposes:
The primary research is conducted with the ecosystem players including, but not limited to:
Finding it difficult to find the research that would cater to your business demands? Give us a chance to help you. One of our Research Consultants will connect to provide a customized solution.
Talk to our research consultant to design an exclusive report as per your research needs.
We aim to fulfil client's research demands with tailored research solutions.
We aim to provide research studies in quickest turnaround time and in a much cost effective manner.
We cover each industry from supply and demand side with an aim to provide a most holistic research study.
We strive to provide most accurate and reliable research findings in our research reports.